Poster Presentation COSA 2015 ASM

Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT). (#364)

Makoto Tahara 1 , Martin Schlumberger 2 , Rossella Elisei 3 , Mouhammed Amir Habra 4 , Naomi Kiyota 5 , Corina Dutcus 6 , Jianbo Xu 7 , Junming Zhu 7 , Taro Hihara 8 , Shannon McGrath 9 , Mark Matijevic 9 , Tadashi Kadowaki 8 , Yasuhiro Funahashi 9 , Brett Hughes 10 , Steven Sherman 4
  1. Division of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan
  2. Department of Nuclear Medicine and Endocrine Oncology, Centre de Reference Tumeurs Refractaires de la Thyroide, Gustave Roussy and University Paris-Sud, Villejuif, France
  3. Dipartimento Di Medicina Clinica e Sperimentale, Universita di Pisa, Pisa, Italy
  4. Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas, MD Anderson Cancer Centre, Houston, Texas, USA
  5. Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan
  6. Oncology Product Creation Unit, Eisai Inc, Woodcliff Lake, NJ, USA
  7. Eisai Inc, Woodcliff Lake, NJ, USA
  8. Eisai Co., Ltd, Tokyo, Japan
  9. Eisai Inc., Andover, Maine, USA
  10. Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
Publish consent withheld